Sunitinib Accord Den europeiske union - norsk - EMA (European Medicines Agency)

sunitinib accord

accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

Teriparatide Sun Den europeiske union - norsk - EMA (European Medicines Agency)

teriparatide sun

sun pharmaceutical industries europe b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - kalsiumhomeostase - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Sunitinib Sandoz 12.5 mg Norge - norsk - Statens legemiddelverk

sunitinib sandoz 12.5 mg

sandoz - københavn - sunitinib - kapsel, hard - 12.5 mg

Sunitinib Sandoz 25 mg Norge - norsk - Statens legemiddelverk

sunitinib sandoz 25 mg

sandoz - københavn - sunitinib - kapsel, hard - 25 mg

Sunitinib Sandoz 50 mg Norge - norsk - Statens legemiddelverk

sunitinib sandoz 50 mg

sandoz - københavn - sunitinib - kapsel, hard - 50 mg

Sunitinib Teva 12.5 mg Norge - norsk - Statens legemiddelverk

sunitinib teva 12.5 mg

teva b.v. - sunitinib - kapsel, hard - 12.5 mg

Sunitinib Teva 25 mg Norge - norsk - Statens legemiddelverk

sunitinib teva 25 mg

teva b.v. - sunitinib - kapsel, hard - 25 mg

Sunitinib Teva 50 mg Norge - norsk - Statens legemiddelverk

sunitinib teva 50 mg

teva b.v. - sunitinib - kapsel, hard - 50 mg

Sitagliptin SUN Den europeiske union - norsk - EMA (European Medicines Agency)

sitagliptin sun

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, type 2 - legemidler som brukes i diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Ertapenem SUN Den europeiske union - norsk - EMA (European Medicines Agency)

ertapenem sun

sun pharmaceutical industries (europe) b.v. - ertapenemnatrium - bakterielle infeksjoner - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 og 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. det bør vurderes å offisielle retningslinjer for riktig bruk av antibakterielle midler.